secwatch.observer — SEC 8-K summary
======================================

Issuer:     STRATA Skin Sciences, Inc. (SSKN)
CIK:        0001051514
Form:       8-K
Filed at:   2024-07-17T23:59:59+00:00
Accession:  0001140361-24-033358
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

STRATA Skin Sciences announces clinical study showing TheraClear X reduces acne lesions by ≥50% after three treatments
--------------------------------------------------------------------------------

- Study in Journal of Cosmetic and Laser Therapy (July 11, 2024) evaluated 7 female patients with mild-moderate acne.
- All patients achieved ≥50% clearance of comedones, pustules, and inflammatory lesions after three treatments.
- Side effects were mild and transient: erythema, bruising, superficial erosions, temporary pigmentation changes (48-72 hours).
- TheraClear X is FDA-cleared as a noninvasive, in-office treatment for mild-to-moderate acne, combining vacuum and broadband light.
- President and CEO Dr. Dolev Rafaeli cited photopneumatic therapy as a viable alternative for patients resistant to traditional treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1051514/000114036124033358/0001140361-24-033358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1051514/000114036124033358/ef20032529_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-033358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer